Changes in serum cholesterol levels determine future risk of cardiovascular events in patients with acute coronary syndrome in the Japanese Coronary Artery Disease (JCAD) Study  by Fukuda, Shota et al.
OC
e
D
S
M
D
a
b
c
d
e
f
g
a
A
R
R
2
A
A
K
C
C
P
I
v
t
l
m
t
r
l
(
7
O
8
0
hJournal of Cardiology 61 (2013) 387–392
Contents lists available at SciVerse ScienceDirect
Journal  of  Cardiology
jo ur nal home page: www.elsev ier .com/ locate / j j cc
riginal  Article
hanges  in  serum  cholesterol  levels  determine  future  risk  of  cardiovascular
vents  in  patients  with  acute  coronary  syndrome  in  the  Japanese  Coronary  Artery
isease  (JCAD)  Study
hota  Fukuda  (MD)a,1,  Kenei  Shimada  (MD,  FJCC)b,∗,1, Masatoshi  Fujita  (MD,  FJCC)c,1,
inoru  Yoshiyama  (MD,  FJCC)b,1,  Junichi  Yoshikawa  (MD,  FJCC)d,1,  Takahide  Kohro  (MD)e,1,
oubun  Hayashi  (MD,  FJCC)e,1,  Tsutomu  Yamazaki  (MD,  FJCC) f,1, Ryozo  Nagai  (MD,  FJCC)g,1
Department of Medicine, Osaka Ekisaikai Hospital, Osaka, Japan
Department of Internal Medicine and Cardiology, Osaka City University School of Medicine, Osaka, Japan
Department of Cardiovascular Medicine, Uji Hospital, Uji, Japan
Nishinomiya Watanabe Cardiovascular Center, Nishinomiya, Japan
Department of Cardiovascular Medicine, University of Tokyo Graduate School of Medicine, Tokyo, Japan
Clinical Research Support Center, The University of Tokyo Hospital, Tokyo, Japan
Jichi Medical University, Tochigi, Japan
 r  t  i  c  l  e  i  n  f  o
rticle history:
eceived 20 September 2012
eceived in revised form
7 November 2012
ccepted 1 February 2013
vailable online 15 March 2013
ey words:
ardiovascular disease
a  b  s  t  r  a  c  t
Background:  Although  increased  attention  is  given  to assess  absolute  values  of  serum  cholesterol  proﬁles
as  optimal  markers  for preventing  future  cardiovascular  (CV)  events,  changes  in  cholesterol  proﬁles  also
have  the  potential  to  be associated  with  CV  disease  outcome  in Japanese  patients  with  acute  coronary
syndrome  (ACS).
Methods: From  the  database  of the  Japanese  Coronary  Artery  Disease  (JCAD)  study,  2664 patients  with  ACS
who had serial  measurements  of serum  cholesterol  proﬁle  parameters  were  enrolled.  These  patients  were
followed-up  for a mean  period  of  2.7  years.  The  endpoint  was  all CV  events.  Baseline  clinical  characteristics
of  patients  with  and  without  CV events  were  adjusted  by the  propensity  score  matching  analysis.holesterol
rognosis
Results:  None  of  the  serum  absolute  cholesterol  proﬁles  at  baseline  and  6 months  later  was associated  with
CV events,  except  for baseline  serum  total  cholesterol  level.  However,  large  improvements  in cholesterol
proﬁles  correlated  with  better  CV  disease  outcome.
Conclusions:  This  subanalysis  of JCAD  demonstrated  the  importance  of  serial  assessment  of  serum  choles-
ry  pr
r  tha
© 2terol  proﬁles  for seconda
cholesterol  proﬁles,  rathe
ntroduction
Serum cholesterol levels are directly associated with cardio-
ascular (CV) events [1,2]. Previous large, randomized, controlled
rials have demonstrated that reductions in serum low-density
ipoprotein-cholesterol (LDL-C) concentrations by 3-hydroxy-3-
ethylglutaryl coenzyme A reductase inhibitors (statins) reduce
he mortality of patients with hypercholesterolemia [3–7]. The cur-
ent guidelines for secondary prevention recommend target LDL-C
evels below 100 mg/dl in patients with coronary artery disease
CAD). More intensive statin therapy targeting an LDL-C level of
0 mg/dl for patients at very high risk for CV disease has been
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n  their  absolute  values,  correlated  with  future  CV events.
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recommended in Western countries [8]. It is therefore clear that
LDL-C reduction by statin therapy is effective for the prevention
of CV disease. However, there is considerable variation in serum
cholesterol levels among patients with acute coronary syndrome
(ACS) events [9], which raises questions about the use of absolute
values of serum cholesterol proﬁles as optimal markers for preven-
tion of future CV events in the setting of ACS. The aim of this study
was to investigate the importance of the extent of reduction in
serum cholesterol proﬁle on secondary prevention of CAD in a large,
Japanese population with ACS. This study is a subanalysis of data
from the Japanese Coronary Artery Disease (JCAD) study [10–12].
MethodsStudy population
The protocol and major outcomes of the JCAD study have
been reported previously [10–12]. Consecutive patients with
llege of Cardiology.
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Table 1
Clinical characteristics of study population and cholesterol proﬁles before propen-
sity score matching.
Events (+)
(n = 324)
Events (−)
(n = 2340)
p-Value
Age (years) 68 ± 10 64 ± 10 <0.001
Gender (male), n (%) 246 (76) 1762 (75) 0.8
Hypertension, n (%) 172 (53) 1223 (52) 0.8
Hyperlipidemia, n (%) 153 (47) 1291 (55) 0.007
Impaired glucose tolerance, n (%) 125 (39) 896 (38) 0.9
BMI  > 25 kg/m2, n (%) 87 (27) 779 (33) 0.02
Smoking, n (%) 133 (41) 1139 (49) 0.01
Family history, n (%) 45 (14) 383 (16) 0.3
Heart failure, n (%) 60 (19) 287 (12) 0.001
Left  main coronary artery, n (%) 18 (5.6) 69 (2.9) 0.01
Number of coronary artery disease 1.9 ± 0.8 1.7 ± 0.8 0.002
Medication
Statins, n (%) 108 (33) 1009 (43) <0.001
-Blockers, n (%) 62 (19) 475 (20) 0.6
Diuretics, n (%) 69 (21) 312 (13) <0.001
CCB,  n (%) 173 (53) 1090 (47) 0.02
ACEIs, n (%) 119 (37) 924 (40) 0.3
ARBs, n (%) 51 (16) 392 (17) 0.6
Aspirin, n (%) 278 (86) 2078 (89) 0.1
Laboratory data
Baseline
CRP (mg/dl) 0.91 ± 2.20 0.74 ± 1.98 0.1
Total cholesterol (mg/dl) 192 ± 39 199 ± 40 0.002
LDL-C (mg/dl) 121 ± 35 128 ± 37 0.006
HDL-C (mg/dl) 47 ± 17 46 ± 15 0.9
LDL/HDL ratio 2.9 ± 1.2 3.1 ± 2.2 0.1
Follow-up at 6 months
CRP (mg/dl) 0.45 ± 1.22 0.26 ± 1.22 0.01
Total cholesterol (mg/dl) 195 ± 40 196 ± 34 0.3
LDL-C (mg/dl) 119 ± 34 118 ± 30 0.9
HDL-C (mg/dl) 48 ± 14 50 ± 14 0.02
LDL/HDL ratio 2.7 ± 1.2 2.6 ± 1.2 0.09
Percent changes during follow-up
CRP (%) −11.7 ± 140.2 −51.1 ± 105.9 <0.001
Total cholesterol (%) 1.2 ± 20.5 −0.4 ± 19.7 0.1
LDL-C (%) 1.9 ± 36.5 −2.8 ± 37.2 0.02
HDL-C (%) 7.7 ± 32.4 13.2 ± 45.1 <0.001
LDL/HDL ratio (%) 10.8 ± 124.1 3.5 ± 89.8 <0.001
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker;
BMI, body mass index; CCB, calcium channel blocker; CRP, C-reactive protein; HDL-C,88 S. Fukuda et al. / Journal o
75% organic stenosis based on the classiﬁcation of the American
eart Association on coronary angiography in at least one branch
oronary artery were enrolled in the JCAD study. A total of 15,628
atients were initially registered, and 13,812 patients were
ollowed-up and included in the analysis (follow-up rate 88.4%).
mong them, the study population of this subanalysis consisted
f 2664 patients (2008 males, mean age 65 ± 10 years) with ACS
hose laboratory data including serum levels of total cholesterol,
DL-C, high-density lipoprotein-cholesterol (HDL-C), and LDL/HDL
atio were available at registration and 6 months later. The percent
hanges in these cholesterol-related parameters during the follow-
p were calculated as (follow-up value − baseline value)/baseline
alue.
tudy design and endpoints
All data, including medical history, medications, risk factors for
AD and results of laboratory tests, were gathered electronically
hrough the internet at registration and every 6 months for 3 years.
atients were followed-up for an average period of 2.7 years. All
nformation were obtained by the attending physicians.
The endpoints of this analysis were all-cause deaths including
ardiac, cerebral, vascular, and other deaths, and cardiac, cere-
ral, and vascular events. Cardiac events were deﬁned as fatal
nd non-fatal myocardial infarction, unstable angina pectoris,
ongestive heart failure, coronary bypass graft surgery, resus-
itated cardiac arrest, and cardiopulmonary arrest on arrival.
ngiographic restenosis incidentally found on routine follow-up
oronary angiography without clinical symptoms was  excluded
rom events registration. Cerebral events included cerebral hem-
rrhage, cerebral infarction, and transient ischemic attack. Aortic
issection and rupture of an aortic aneurysm were classiﬁed as
ascular events.
tatistical analysis
Categorical variables are presented as number (%) and con-
inuous variables as mean ± SD. The chi-square test was  used for
omparison of categorical variables and the Wilcoxon test for
npaired continuous variables. Propensity score matching analy-
is was used to match baseline characteristics between two groups.
ox proportional hazard analysis was performed to identify predic-
ors of CV events. Baseline variables that were considered clinically
elevant or that showed a univariate relationship with outcome
ere entered into the analysis. Cumulative event rates were esti-
ated by the Kaplan–Meier survival curves to compare cumulative
ncidence of CV events from 6 months after enrollment of JCAD
tudy, and the log-rank test was used to assess group differences.
ifferences were considered signiﬁcant at p < 0.05.
esults
Patient characteristics and laboratory data of patients with and
ithout events before and after propensity score matching are
ummarized in Tables 1 and 2, respectively. After propensity score
atching, there were signiﬁcant differences in certain clinical char-
cteristics between patients with and without events at baseline
nd 6 months later. Patients with events had larger decreases in
erum C-reactive protein (CRP) and LDL/HDL ratio and increases
n HDL-C than those without events. When LDL-C and HDL-C were
sed as the parameters of cholesterol proﬁle, Cox proportional haz-
rd analysis showed that advanced age, history of heart failure, and
ecreases in HDL-C were independent factors associated with CV
vents (Table 3, model 1). When Cox proportional hazard analysis
as repeated with LDL/HDL ratio, the change in LDL/HDL ratio was
dentiﬁed as an independent risk for CV events (Table 3, model 2).high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.
The baseline values of LDL-C, HDL-C, and LDL/HDL ratio were not
signiﬁcant independent predictors of future CV events in both uni-
variate (Table 2) and multivariate Cox proportional hazards models
(Table 3).
The cumulative incidence of CV events during the follow-up
period in the quartiles was  compared in terms of serum levels of
total cholesterol, LDL-C, and HDL-C, and LDL/HDL ratio. At base-
line (Fig. 1), patients with serum total cholesterol levels >223 mg/dl
had a lower incidence of CV events than those with serum total
cholesterol levels <170 mg/dl. There were no differences in LDL-
C, HDL-C, and LDL/HDL ratio at baseline between those with and
without events. At 6-month follow-up, there were no differences
in the event rate irrespective of any cholesterol parameter (Fig. 2).
In contrast, patients with >4% LDL-C reduction during the follow-
up had lower event rate than those with >14% increase of LDL-C
level (Fig. 3). Additional CV event reduction was not seen when
LDL-C decreased greater than 21%. A rise of more than 6% in HDL-C
was associated with a benign outcome. On the other hand, a fall of
more than 9% in LDL/HDL ratio was associated with reduced event
rate, although a reduction of >30% did not provide further beneﬁcial
effect in the event rate.
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Table  2
Clinical characteristics of study population and cholesterol proﬁles after propensity
score matching.
Events (+)
(n = 308)
Events (−)
(n = 308)
p-Value
Age (years) 68 ± 10 69 ± 9 0.8
Gender (male), n (%) 236 (77) 241 (78) 0.6
Hypertension, n (%) 165 (54) 168 (55) 0.8
Hyperlipidemia, n (%) 148 (48) 156 (51) 0.5
Impaired glucose tolerance, n (%) 116 (38) 105 (34) 0.4
BMI  > 25 kg/m2, n (%) 81 (26) 79 (26) 0.9
Smoking, n (%) 124 (40) 128 (42) 0.7
Family history, n (%) 43 (14) 51 (17) 0.4
Heart failure, n (%) 58 (19) 61 (20) 0.8
Left  main coronary artery, n (%) 18 (5.8) 15 (4.9) 0.6
Number of coronary artery disease 1.9 ± 0.9 1.9 ± 0.8 0.6
Medication
Statins, n (%) 106 (34) 121 (39) 0.2
-Blockers, n (%) 59 (19) 65 (21) 0.5
Diuretics, n (%) 64 (21) 63 (21) 0.9
CCB, n (%) 166 (54) 157 (51) 0.5
ACEIs, n (%) 113 (37) 122 (40) 0.5
ARBs, n (%) 50 (16) 45 (15) 0.6
Aspirin, n (%) 263 (85) 266 (86) 0.7
Laboratory data
Baseline
CRP (mg/dl) 0.85 ± 2.01 0.70 ± 1.70 0.1
Total cholesterol (mg/dl) 193 ± 40 194 ± 34 0.4
LDL-C (mg/dl) 122 ± 35 123 ± 30 0.4
HDL-C (mg/dl) 46 ± 17 46 ± 13 0.5
LDL/HDL ratio 2.9 ± 1.2 2.9 ± 1.0 0.9
Follow-up at 6 months
CRP (mg/dl) 0.46 ± 1.25 0.36 ± 1.13 0.3
Total cholesterol (mg/dl) 194 ± 39 192 ± 32 0.6
LDL-C (mg/dl) 119 ± 33 116 ± 29 0.5
HDL-C (mg/dl) 47 ± 13 50 ± 15 0.07
LDL/HDL ratio 2.8 ± 1.2 2.6 ± 1.0 0.06
Percent changes during follow-up
CRP (%) −10.3 ± 142.6 −56.3 ± 93.0 0.001
Total cholesterol (%) 1.0 ± 20.5 0.2 ± 18.6 0.5
LDL-C (%) 1.7 ± 36.7 −2.7 ± 29.2 0.2
HDL-C (%) 8.0 ± 33.0 11.2 ± 28.3 0.03
LDL/HDL ratio (%) 10.9 ± 127.0 −6.0 ± 48.8 0.005
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker;
BMI, body mass index; CCB, calcium channel blocker; CRP, C-reactive protein; HDL-C,
high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.
Table 3
Cox proportional hazard analysis for developing CV events.
Hazard ratio (95% CI) p-Value
Model 1
Age (years) 1.03 (1.02–1.07) <0.0001
History of heart failure 1.45 (1.08–1.15) 0.02
Baseline LDL-C (mg/dl) 1.00 (0.99–1.67) 0.5
Changes in LDL-C (%) 1.24 (0.98–1.05) 0.08
Baseline HDL-C (mg/dl) 0.99 (0.98–1.25) 0.1
Changes in HDL-C (%) 0.64 (0.41–1.34) 0.046
Model 2
Age (years) 1.04 (1.02–1.07) <0.0001
History of heart failure 1.42 (1.06–1.67) 0.02
Baseline LDL/HDL ratio (%) 0.99 (0.92–1.05) 0.8
Changes in LDL/HDL ratio 1.07 (1.01–1.25) 0.03
Adjusted for gender, hypertension, diabetes, body mass index, smoking status, fam-
ily  history, and history of heart failure. The variables entered into Cox proportional
hazards included LDL-C and HDL-C in model 1. Cox proportional hazard analysis was
then repeated with LDL/HDL ratio (model 2). CI, conﬁdence interval; CV, cardiovas-
cular; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein
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Discussion
This study is a sub-analysis of the JCAD study showing that
changes in serum cholesterol proﬁles during 6 months were asso-
ciated with future CV events in patients with a history of ACS,
rather than absolute values of cholesterol proﬁles at the time of
ACS occurrence or 6 months later.
Cholesterol-lowering therapy using statins offers clinical bene-
ﬁts for primary [4,5] and secondary prevention [3,6] of CV events
in patients with hypercholesterolemia. Attention has increasingly
focused on deﬁning optimal target levels of absolute LDL-C value,
100 mg/dl or 70 mg/dl [8]. However, in this study, the percent
reduction in LDL-C and increases in HDL-C were associated with
improved secondary prevention of CV disease outcome in ACS
patients in a Japanese population; these parameters were superior
to the absolute values of cholesterol proﬁle parameters. This ﬁnding
adds support to the results of previous large studies from West-
ern countries showing that baseline cholesterol proﬁles were not
associated with CV disease outcome [4,6,13]. Why  does the percent
change better relate with the outcome than the absolute value? It
is possible that a larger reduction in LDL-C may  simply have a more
potent beneﬁcial effect on atherosclerotic plaques, preventing CV
events. Although intensive statin therapy has a favorable effect on
coronary plaque morphology [14,15], the effect of cholesterol low-
ering on CV risk reduction remains speculative. This discrepancy
probably reﬂects the wide range of beneﬁcial biologic effects of
statins, in addition to cholesterol-lowering action, in preventing
CV events.
Another potential explanation is that the response to statin
therapy varies among individuals. Various parameters have been
reported to contribute to the variations in cholesterol proﬁles in
response to statin treatment, such as age [16–18], smoking sta-
tus, [17,18], body weight [16,19], insulin resistance [19], and gene
expression [18,20,21]. Interestingly, these factors are also asso-
ciated with the development of atherosclerosis and CV disease
outcome. Consequently, the percent reduction in cholesterol is
meaningful in preventing CV events in patients with ACS, beyond
baseline cholesterol levels. These observations stress the impor-
tance of cholesterol management by statin therapy, even in patients
with ACS, whose LDL-C is at near-normal or normal levels [22–24].
Serial measurements of cholesterol proﬁles help in the manage-
ment of patients with ACS for secondary prevention of CV events.
Further, it is reported that oxidized LDL plays a key role in
the pathogenesis of coronary atherosclerosis [25,26]. Ky et al.
demonstrated that the correlation between both percent changes in
oxidized LDL and LDL-C by statins (r2 = 0.68, p < 0.001) was stronger
than that between both absolute values (r2 = 0.46, p < 0.001) in 120
patients with LDL-C levels between 130 mg/dl and 220 mg/dl [27].
Tavridou et al. also showed that changes in oxidized LDL levels
signiﬁcantly related to those in LDL-C in 22 patients with total
cholesterol levels >200 mg/dl and triglycerides >150 mg/dl (r = 0.58,
p = 0.01), while no signiﬁcant correlation between both absolute
values was  evident (r = 0.25, p = 0.29) [28]. These ﬁndings might
explain the observations in this study.
Patients with serum total cholesterol levels >223 mg/dl had a
lower incidence of CV events than those with serum total choles-
terol levels <170 mg/dl, which might be inconsistent with previous
observations in the pre-statin era [1,2,29,30]. This ﬁnding may be
explained by the relatively low ratio of statin used in this study
(approximately 40%). Statin therapy was prescribed based on the
cholesterol proﬁles presented during study enrollment for the JCAD
study, which was  initiated in 2000. Statin therapy led to a decrease
in total cholesterol in patients who presented with high levels
at enrollment, whereas patients with near-normal or normal lev-
els of cholesterol were less likely to have initiated statin therapy
upon study enrollment or during the follow-up period. Changes in
390 S. Fukuda et al. / Journal of Cardiology 61 (2013) 387–392
Fig. 1. Comparison of cumulative incidence of CV events by quartiles of serum cholesterol proﬁle at baseline. CV, cardiovascular; HDL-C, high-density lipoprotein cholesterol;
LDL-C,  low-density lipoprotein cholesterol.
Fig. 2. Comparison of cumulative incidence of CV events by quartiles of serum cholesterol proﬁle at 6-month follow-up. CV, cardiovascular; HDL-C, high-density lipoprotein
cholesterol; LDL-C, low-density lipoprotein cholesterol.
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rescriptions during the follow-up period were not assessed in the
resent study. Another JCAD observational study has conﬁrmed the
ncreasing trends of statin use from 37% in 2000 to 50% in 2003 [31].
onsidering current, widespread use of statin therapy, the results
f this study should be interpreted carefully.
Additional CV event reduction was not seen when LDL-C
ecreased greater than 21% in this study. On the other hand,
ncremental beneﬁts of intensive statin therapy on long-term CV
utcomes have been reported in Western populations [32,33].
n Japan, several studies have used intravascular ultrasound to
emonstrate the regression of coronary plaque that results when
DL-C levels were controlled at approximately 70–80 mg/dl [14,34].
owever, whether decreased levels of LDL-C lead to improved clin-
cal outcomes in patients with CAD in the Japanese population
emains unclear [35,36]. Because the JCAD study was an observa-
ional study, emerging prospective and randomized investigations
ay  soon provide answers to this question.
tudy limitations
This study was a sub-analysis of the JCAD study, which is
n observational rather than randomized study. Propensity score
atching was used to eliminate the possible effect of confounding
actors on the results. However, other factors that were not mea-
ured may  affect the results of this study. Second, statins have a
ariety of beneﬁcial biologic actions in addition to their cholesterol-
owering activity. These actions vary according to the different
tatins based on their pharmacological properties, which should
e taken into consideration in future studies. Finally, the labora-
ory tests were only repeated 6 months after the baseline study, andhanges in serum cholesterol proﬁle during follow-up. CV, cardiovascular; HDL-C,
a longer follow-up period is needed for a better evaluation of the
effects of treatment on the cholesterol proﬁle. For example, choles-
terol level may  increase in some patients with increased cholesterol
absorption during long-term statin therapy [37], which may  affect
the long-term CV disease outcome [38,39].
Conclusions
This study demonstrated the superiority of assessment of the
percent changes in LDL-C and HDL-C over a period of time com-
pared with measurement of absolute values of cholesterol proﬁles,
in providing prognostic information on secondary prevention of CV
events in Japanese patients with ACS.
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